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a  b  s  t  r  a  c  t
Sinus augmentation is a preprosthetic technique for rehabilitating posterior sector of the
atrophied maxilla with implant-supported prosthesis. We  retrospectively analyzed 34 con-
secutive sinus augmentations performed using only bovine hydroxyapatite.
The  presurgical height in 92% of the cases was 4 mm or less.
The success rate of the maxillary sinus augmentation was 100% for this technique. 13.4%
of  the implants were placed immediately with a success rate of implants placement of
93.9%. The non-osseointegrated implants were all successfully replaced. Follow-up period
was  1268 days.
The success rate obtained using bovine hydroxyapatite alone is similar to that using other
types of materials, while avoids morbidity of the autologous bone donor area.
©  2014 SECOM. Published by Elsevier España, S.L.U. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Elevación  del  seno  maxilar  con  hidroxiapatita  bovina  sola:  Una  técnica
segura  con  resultados  predecibles  en  pacientes  con  atroﬁa  maxilar  grave
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r  e  s  u  m  e  n
La elevación del seno es una técnica preprotésica para la rehabilitación del sector posterior
atroﬁado del maxilar con una prótesis de implantación. Analizamos retrospectivamente 34
casos consecutivos de elevación del seno maxilar con el empleo de tan solo hidroxiapatita
bovina sola.
La altura prequirúrgica era de 4 mm o menos en el 92% de los casos.
El  porcentaje de éxitos de la elevación del seno maxilar con esta técnica fue del 100%.
Un  13,4% de los implantes se colocaron inmediatamente, con un porcentaje de éxitos de la
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implantación del 93,9%. Los implantes no osteointegrados se sustituyeron todos con éxito.
El periodo de seguimiento fue de 1268 días.
El porcentaje de éxitos obtenido con el empleo de hidroxiapatita bovina sola es similar
al de otros tipos de materiales, al tiempo que se evita la morbilidad en el área donante de
hueso autólogo.
© 2014 SECOM. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access
bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Sinus augmentation was ﬁrst reported by Tatum in 1976
and subsequently described by Boyne and James in 1980.1,2
It is a preprosthetic technique to increase the height of
the lateral and posterior sectors of atrophied maxillas for
their rehabilitation with implant-supported prostheses. It is
a predictable technique to restore sufﬁcient bone volume for
implant placement.3
The etiology of maxillary bone resorption is multifactorial
and inﬂuenced by age, bone diseases, and tooth extractions.
Thus, bone resorption continues after tooth extraction, pro-
ducing a decrease in height and width. With the decrease in
bone height, the remnant bone narrows and becomes closer
to the nasal cavity, maxillary sinuses, and the group of nerves
of the incisive canal.4 Patients with severe maxillary atrophy
are subject to changes in masticatory, swallowing and speech
function, and these changes can often result in psychological
problems.
During the maxillary sinus ﬂoor elevation procedure, the
space created between the residual maxillary ridge and the
elevated Schneiderian membrane is usually ﬁlled with graft-
ing material. In this way, a bone fraction is created that may
allow for reliable implant placement, either simultaneously
with the elevation procedure when the residual ridge allows
for primary implant stability or as a second stage after healing
of the grafted site.5
The utilization of different ﬁlling materials has been
reported after augmentation. The autologous graft is the gold
standard, given its osteogenic, osteoinductive, and osteocon-
ductive properties. It can be obtained from different areas,
including retromolar trigone, chin, or iliac crest. Other options,
such as allografts, xenografts, and alloplastic materials, have
also been widely reported in the literature.
Recent studies analyzed maxillary sinus ﬁlling with
periosteal cell grafts from the lateral jaw.6 Some authors have
also supported the non-utilization of cavity ﬁlling.7
Other available techniques to increase the maxillary height
include bone splitting, bone sandwich graft after LeFort-type
osteotomy, and onlay grafts.
The objective of this study was to retrospectively analyze
sinus augmentations performed with biomaterial alone as
well as the implants success rate. We  also describe different
complications that were observed during the procedure.
Materials  and  methods
This retrospective study included 34 consecutive sinus aug-
mentations performed with biomaterial alone from 2008
through 2011.
All surgeries were performed by the same surgeon.
Outcomes were evaluated by a maxillofacial surgeon not con-
nected with the clinic, based on radiological images and
clinical records. In all patients, the bone quality of the pos-
terior maxilla was type 4 according to Misch’s classiﬁcation.8
Out of 95 sinus augmentations performed with autolo-
gous bone ﬁlling, a mixture of bone with hydroxyapatite, or
bovine hydroxyapatite alone, we  selected 34 augmentations
that used bovine hydroxyapatite alone. 61 sinus augmentation
were rejected due to the use of a mixture of materials. In these
patients, we inserted 84 titanium implants with RBM-treated
surface, external hexagon and standard platform.
Data were gathered on the sex, age, concomitant diseases,
pre- and post-augmentation height, time interval between
sinus augmentation and implant placement, timing of pros-
thetic loading, complications during surgery, and implant
losses.
In all patients, an initial panoramic X-ray and CT scan were
performed to yield the maximum possible information on the
sinus anatomy and to rule out associated disease. All patients
subsequently underwent another panoramic X-ray and/or CT
scan.
Bone gain was measured manually in the panoramic X-ray
at 180 days (the magniﬁcation was taken into account).
Surgical  protocol
All procedures were conducted under local anesthesia (arti-
caine with adrenalin).
The surgery consisted of a crestal incision with anterior
and posterior release incisions. The mucoperiosteal ﬂap was
lifted and the Caldwell-Luc procedure was performed for lat-
eral access (Fig. 1), preparing an oval osteotomy (Fig. 2) with
a tungsten bur and irrigating with saline solution; perforation
of Schneider’s membrane was avoided by carefully detaching
it from the sinus walls with membrane elevators.
A oxidized cellulose polymer layer was placed on the aug-
mented sinus ﬂoor in order to isolate possible undetected
microperforations (Fig. 3), and the cavity was then ﬁlled with
two bovine hydroxyapatite vials and compacted (Fig. 4). A
resorbable collagen membrane of equine origin was placed
for the correct isolation of the area. No periodontal dressing
material was used.
None of the patients had sinus pathology.
All patients were treated with amoxicillin–clavulanic acid
(clindamycin for allergic patients) before and after the
procedure.9 They started the treatment an hour before the
surgery with amoxicillin 875 mg-clavulanic acid 125 every 8 h
and they completed 7 days of treatment. 0.12% chlorhexidine
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Fig. 1 – Access to the sinus after mucoperiosteal ﬂap lift.
Fig. 2 – Lateral osteotomy.
Fig. 3 – Methylcellulose lamina placing on the sinus ﬂoor.
as an oral rinse for ten days was used as well. Sutures were
removed at one week post-surgery.
Results
The study included 34 patients, in whom 37 sinus augmenta-
tions were conducted; 75% were female (Fig. 5), the mean age
Fig. 4 – Filling with hydroxyapatite.
Distribution by sex
Man Woman
Fig. 5 – Distribution by sex.
was 54 years, and 14.7% of patients were smokers (Fig. 6). One
patient was diabetic and one had a history of bisphosphonate
treatment that had been suspended more  than six months
before the surgery.
Three Schneider membranes were perforated (8.1%) dur-
ing the sinus augmentation procedure, and one implant was
lost during the osseointegration period. There was no relation
between the perforation cases and the implant lost.
There were no cases of postsurgical infection and no oral-
sinus communication (Fig. 7).
The mean sinus bone height was 3.1 mm at baseline (i.e.,
most sinuses were severely resorbed) (Figs. 8 and 9) and
11.2 mm post-treatment. A success rate of 100% was obtained
for this technique.
Eighty-two implants were placed (all of them were from
the same trademark); only 13.4% were placed immediately
(height of >4 mm),  given the severe maxillary atrophy (92%)
in the majority of the patients.
Five implants were lost during the osseointegration period,
giving a success rate of 93.9%; these non-osseointegrated
implants were all successfully replaced. The implants were
loaded at a mean of 143 days after their placement (Fig. 10),
and the mean follow-up period was 1268 days (range, 396–2778
days). The different sizes places are seen in the chart (Fig. 11).
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Distribution by tobacco habit
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Fig. 6 – Distribution by tobacco habit.
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Fig. 7 – Surgical complications.
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Fig. 8 – Pre-surgery height of the maxillary sinus.
Fig. 9 – Pre-surgical atrophic maxillary sinus.
Fig. 10 – X-ray image after prosthesis loading.
Implants
3,75 x 11,5mm
3,75 x 13mm
4,25 x 10mm
4,25 x 11,5mm
4,25 x 13mm
Fig. 11 – Implants.
X X X(X X):XXX–XXX4 –92
r e v e s p c i r o r a l m a x i l o f a c .  2 0 1 5;3  7(2):87–92 91
No implant failure rate was observed in patients with
comorbidity or tobacco habit.
Discussion
The aim of sinus augmentation is to increase the height of the
posterior and lateral sectors of the maxilla to permit implant
placement for the rehabilitation of patients with atrophic
maxilla. Given the concomitant morbidity and rapid resorp-
tion of autogenous bone, usually endochondral bone, various
bone substitutes have been studied,10 including a mixture of
autologous bone with hydroxyapatite, hydroxyapatite alone,
ceramic materials, and methylcellulose, among others.
Some authors found that the use of bovine hydroxyapatite
avoids donor area morbidity while offering a similar implant
success rate to that obtained with other materials; these
studies, published in 2005, found no signiﬁcant differences
between sinus augmentation with tricalcium phosphate or
autologous bone grafts.10,11 Bovine hydroxyapatite, which has
osteoconductive properties, is obtained from bovine bone in
which the organic component has been completely removed.
It is believed that the thermal and chemical treatment used to
extract this component produces losses in antigenicity and in
the potential inﬂammatory response.
In comparison to autologous bone grafts (e.g., from iliac
crest or parietal bone), the use of bovine hydroxyapatite avoids
the need for general anesthesia during surgery and precludes
donor area morbidity.
Thus, there are authors who believe that there is no reason
to prefer autogenous bone over bone substitutes.12
It has been studied the maxillary sinus lift with out any
graft material, but in critic defects, the Oliveira et al. conclude
that the poor bone gain results are mainly associated with
insufﬁcient bone quality and the large scope of the defects.13
It is remarkable that in Rickerts’ metaanalyses published in
2011 comparing the bone fraction after applying: autogenous
bone and bone substitutes (bovine hydroxyapatite, bioactive
glass, corticocancellous pig bone) revealed no signiﬁcant dif-
ferences in bone formation after ﬁve months.14 Zijderveld
et al.12 concluded that the sinus augmented with autogenous
bone, the newly formed bone was signiﬁcantly higher than
in the b-tricalciumphosphate group after the same healing
period.
Membrane perforation was observed in 8.1% of our
cases with size less than 2 mm.  This is the most frequent
complication,15 and was recorded in 10.1% of cases by Cho-Lee
et al.15 and in 18.42% of cases by Herrero et al.16 The placement
of an oxidized cellulose polymer layer beneath the lifted mem-
brane can be beneﬁcial for isolating the bovine hydroxyapatite.
In addition, oxidized cellulose polymer layer adheres to and
seals the sinus membrane, which may explain the absence
of infections in the present patients, but further studies are
needed.
There are no major differences between our implant suc-
cess rate and those obtained by other authors. Thus, the
global success rate reported by Cho-Lee et al. in their ret-
rospective study of different ﬁlling materials was 96.91%, in
comparison to 93.1% in the present study. However, in con-
trast to our series, the mean height before treatment was
6.59 mm,  enabling immediate implant placement in 64.7% of
the patients due to the higher primary stability that could be
achieved. In the present study, in which the mean height was
much lower (3.1 mm),  only 13.4% of implants could be placed
in the same surgical act. Sakka et al. obtained a 94.8% success
rate in patients undergoing sinus augmentation with parietal
bone ﬁlling.17 In 2011, Herrero et al.16 achieved an implant suc-
cess rate 96.4% but the mean presurgical height, which was not
reported, was likely much greater than in the present study,
given that an immediate implant could be placed in 89.53% of
their cases.
Chen only places immediate dental implants in a sinus
with at least 5 mm.18
Our implant success in severely resorbed sinuses using
bovine hydroxyapatite alone is within the range reported by
other authors. This procedure does not require general anes-
thesia and avoids patient morbidity.
According to these study ﬁndings, sinus augmentation
with bovine hydroxyapatite alone is a safe surgical technique
that yields a very high implant success rate. This approach
is not associated with any donor morbidity and achieves the
predictable rehabilitation of patients with absence of posterior
sectors in a severely atrophied maxilla. Histological and histo-
morphometrical analysis would be helpful in order to obtain
the bone gain.
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